SCYNEXIS, Inc. SCYX
SCYNEXIS, Inc. (Nasdaq: SCYX) is a rare genetic drug developer. Its lead program, SCY-770, is in Phase 1 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). Its next catalyst on record is SCY-770: Phase 2 proof-of-concept study initiation (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SCY-770 — Phase 2 proof-of-concept study initiation (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BREXAFEMME (ibrexafungerp) | vulvovaginal candidiasis (licensed to GSK) | small molecule | Approved |
| SCY-770 | ADPKD | small molecule | Phase 1 |
| SCY-247 (oral and IV) | invasive candidiasis and prevention of invasive fungal infections | small molecule | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 rare genetic companies
- Prime Medicine, Inc. PRME
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.